Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Carboplatin"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 1382
Tytuł:
[Dose-dense paclitaxel plus carboplatin in combination with trastuzumab neoadjuvant versus standard adjuvant therapy in human epidermal growth factor receptor-2 positive and hormone receptor negative breast cancer: a prospective cohort study].
Autorzy:
Xiu M; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Lu Y; Department of Medical Oncology, the First People's Hospital of Nanning, Nanning 530016, China.
Wang X; Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Fan Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Li Q; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Li Q; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Wang JY; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Luo Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Cai RG; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Chen SS; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Yuan P; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Ma F; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Xu BH; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhang P; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Pokaż więcej
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2023 Aug 23; Vol. 45 (8), pp. 709-716.
Typ publikacji:
English Abstract; Journal Article
MeSH Terms:
Carboplatin*/therapeutic use
Paclitaxel*/therapeutic use
Triple Negative Breast Neoplasms*/drug therapy
Female ; Humans ; Anthracyclines/therapeutic use ; Antibiotics, Antineoplastic/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemotherapy, Adjuvant ; Hormones/therapeutic use ; Neoadjuvant Therapy ; Prospective Studies ; Receptor, ErbB-2/metabolism ; Trastuzumab/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A survey of carboplatin desensitization therapy in Japan: A multicenter retrospective study.
Autorzy:
Komatsu H; Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Tottori, Japan.
Matsumoto K; Department of Medical Oncology, Hyogo Cancer Center, Akashi, Hyogo, Japan.
Morita M; Department of Medical Oncology, Hyogo Cancer Center, Akashi, Hyogo, Japan.
Nagasawa T; Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Iwate, Japan.
Nishio H; Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
Suzuki J; Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.
Nishio S; Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan.
Kobara H; Department of Obstetrics and Gynecology, Shinshu University, Nagano, Japan.
Yunokawa M; Department of Gynecology, The Cancer Institute Hospital of JFCR, Tokyo, Japan.
Ariyoshi K; Department of Gynecology Service, National Kyushu Cancer Center, Fukuoka, Japan.
Hirayama T; Department of Obstetrics and Gynecology, Juntendo University Hospital, Tokyo, Japan.
Tokunaga H; Department of Gynecology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Ukita M; Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yoriki K; Department of Obstetrics and Gynecology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Mori-Uchino M; Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Furusawa A; Department of Gynecology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Togami S; Department of Obstetrics and Gynecology, Faculty of Medicine, Kagoshima University, Kagoshima, Japan.
Nakamura H; Department of Obstetrics and Gynecology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan.
Ishikawa M; Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan.
Satoh T; Department of Obstetrics and Gynecology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2024 Mar; Vol. 13 (5), pp. e6968.
Typ publikacji:
Journal Article; Multicenter Study; Observational Study
MeSH Terms:
Antineoplastic Agents*/adverse effects
Drug Hypersensitivity*/epidemiology
Drug Hypersensitivity*/etiology
Uterine Cervical Neoplasms*/drug therapy
Female ; Humans ; Carboplatin ; Erythema/chemically induced ; Erythema/complications ; Erythema/drug therapy ; Japan/epidemiology ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
ZSWIM4 inhibition improves chemosensitivity in epithelial ovarian cancer cells by suppressing intracellular glycine biosynthesis.
Autorzy:
Gong K; Institute of Reproductive Health and Perinatology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China.; Department of Gynecology and Obstetrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, Guangdong, China.
Huang Y; School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, Guangdong, China.
Zheng Y; Department of Gynecology and Obstetrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, Guangdong, China.
Hao W; Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, Guangdong, China. .
Shi K; Institute of Reproductive Health and Perinatology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. .; Department of Gynecology and Obstetrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, Guangdong, China. .
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2024 Feb 21; Vol. 22 (1), pp. 192. Date of Electronic Publication: 2024 Feb 21.
Typ publikacji:
Journal Article
MeSH Terms:
Ovarian Neoplasms*/drug therapy
Ovarian Neoplasms*/genetics
Ovarian Neoplasms*/pathology
Neoplasms, Glandular and Epithelial*
Animals ; Humans ; Female ; Carcinoma, Ovarian Epithelial/drug therapy ; Carcinoma, Ovarian Epithelial/genetics ; Carcinoma, Ovarian Epithelial/metabolism ; Carboplatin/therapeutic use ; Cell Line, Tumor ; Prognosis ; Cell Proliferation ; Gene Expression Regulation, Neoplastic ; Forkhead Transcription Factors/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Platinum(IV) Prodrugs Incorporating an Indole-Based Derivative, 5-Benzyloxyindole-3-Acetic Acid in the Axial Position Exhibit Prominent Anticancer Activity.
Autorzy:
Aputen AD; School of Science, Western Sydney University, Sydney, NSW 2751, Australia.
Elias MG; School of Science, Western Sydney University, Sydney, NSW 2751, Australia.; Ingham Institute, Sydney, NSW 2170, Australia.
Gilbert J; Calvary Mater Newcastle Hospital, Newcastle, NSW 2298, Australia.
Sakoff JA; Calvary Mater Newcastle Hospital, Newcastle, NSW 2298, Australia.
Gordon CP; School of Science, Western Sydney University, Sydney, NSW 2751, Australia.
Scott KF; Ingham Institute, Sydney, NSW 2170, Australia.; School of Medicine, Western Sydney University, Sydney, NSW 2751, Australia.
Aldrich-Wright JR; School of Science, Western Sydney University, Sydney, NSW 2751, Australia.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 11; Vol. 25 (4). Date of Electronic Publication: 2024 Feb 11.
Typ publikacji:
Journal Article
MeSH Terms:
Prodrugs*/chemistry
Antineoplastic Agents*/chemistry
Hydroxyindoleacetic Acid/*analogs & derivatives
Humans ; Cisplatin/pharmacology ; Platinum/chemistry ; Oxaliplatin/pharmacology ; Carboplatin/pharmacology ; Carboplatin/chemistry ; Cell Line, Tumor
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Mesonephric-like adenocarcinoma of the ovary.
Autorzy:
Yang Y; Dalian Medical University, Dalian, 116000, PR China.
Zhao M; Dalian Medical University, Dalian, 116000, PR China.
Jia Q; Department of Gynecology, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, 213003, PR China.
Tang H; Department of Gynecology, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, 213003, PR China.
Xing T; Department of Gynecology, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, 213003, PR China.
Li Y; Department of Gynecology, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, 213003, PR China.
Tang B; Department of Gynecology, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, 213003, PR China.
Xu L; Department of Gynecology, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, 213003, PR China.
Wei W; Department of Gynecology, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, 213003, PR China.
Zheng H; Department of Gynecology, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, 213003, PR China.
Shi R; Department of Gynecology, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, 213003, PR China.
Xia B; Department of Gynecological Oncology, Division of Life Sciences and Medicine, the First Affiliated Hospital of University of Science and Technology of China, University of Science and Technology of China, Hefei, 230031, PR China. .
Chen J; Department of Gynecology, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, 213003, PR China. .
Pokaż więcej
Źródło:
Journal of ovarian research [J Ovarian Res] 2024 Mar 05; Vol. 17 (1), pp. 57. Date of Electronic Publication: 2024 Mar 05.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Ovarian Neoplasms*/diagnosis
Ovarian Neoplasms*/therapy
Adenocarcinoma*/diagnosis
Adenocarcinoma*/therapy
Female ; Humans ; Middle Aged ; Pelvis ; Carboplatin
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Benefits of camrelizumab plus carboplatin and albumin paclitaxel as induction therapy for locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma.
Autorzy:
Chao L; Department of Thoracic Surgery, Shanxi Cancer Hospital, Taiyuan, PR China.
Liu J; Department of Thoracic Surgery, Shanxi Cancer Hospital, Taiyuan, PR China.
Chen Y; Department of Thoracic Surgery, Shanxi Cancer Hospital, Taiyuan, PR China.
Fan Y; Department of Thoracic Surgery, Shanxi Cancer Hospital, Taiyuan, PR China.
Guo S; Department of Thoracic Surgery, Shanxi Cancer Hospital, Taiyuan, PR China.
Zhang S; Department of Thoracic Surgery, Shanxi Cancer Hospital, Taiyuan, PR China.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2024 Mar; Vol. 15 (8), pp. 622-629. Date of Electronic Publication: 2024 Feb 05.
Typ publikacji:
Journal Article
MeSH Terms:
Esophageal Squamous Cell Carcinoma*/drug therapy
Esophageal Squamous Cell Carcinoma*/surgery
Esophageal Neoplasms*/drug therapy
Esophageal Neoplasms*/surgery
Esophageal Neoplasms*/pathology
Antibodies, Monoclonal, Humanized*
Humans ; Carboplatin/therapeutic use ; Paclitaxel/pharmacology ; Paclitaxel/therapeutic use ; Retrospective Studies ; Induction Chemotherapy ; Neoadjuvant Therapy ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Albumins/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Adjuvant carboplatin and paclitaxel with "sandwich" method radiotherapy for stage III or IV endometrial cancer: long-term follow-up at a single-institution.
Autorzy:
Chinnadurai A; Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
Breadner D; London Regional Cancer Program, London Health Sciences Centre, Victoria Hospital, London, ON, Canada.; Department of Oncology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada. .
Baloush Z; London Regional Cancer Program, London Health Sciences Centre, Victoria Hospital, London, ON, Canada.
Lohmann AE; London Regional Cancer Program, London Health Sciences Centre, Victoria Hospital, London, ON, Canada.
Black M; London Regional Cancer Program, London Health Sciences Centre, Victoria Hospital, London, ON, Canada.
D'Souza D; London Regional Cancer Program, London Health Sciences Centre, Victoria Hospital, London, ON, Canada.; Department of Oncology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
Welch S; London Regional Cancer Program, London Health Sciences Centre, Victoria Hospital, London, ON, Canada.; Department of Oncology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
Pokaż więcej
Źródło:
Journal of gynecologic oncology [J Gynecol Oncol] 2024 Mar; Vol. 35 (2), pp. e16. Date of Electronic Publication: 2023 Oct 16.
Typ publikacji:
Journal Article
MeSH Terms:
Paclitaxel*
Endometrial Neoplasms*/drug therapy
Endometrial Neoplasms*/radiotherapy
Adult ; Humans ; Female ; Middle Aged ; Aged ; Aged, 80 and over ; Carboplatin ; Follow-Up Studies ; Cohort Studies ; Retrospective Studies ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Neoplasm Staging ; Chemotherapy, Adjuvant/methods ; Radiotherapy, Adjuvant
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Exposure to select PFAS and PFAS mixtures alters response to platinum-based chemotherapy in endometrial cancer cell lines.
Autorzy:
Rickard BP; Curriculum in Toxicology & Environmental Medicine, University of North Carolina School of Medicine, University of North Carolina at Chapel Hill, 116 Manning Drive, Chapel Hill, NC, 27599, USA.; Mechanistic Toxicology Branch, Division of Translational Toxicology, National Institute of Environmental Health Sciences, 111 T.W. Alexander Drive, Research Triangle Park, Durham, NC, 27709, USA.
Overchuk M; Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill, 116 Manning Drive, Chapel Hill, NC 27599, USA; Engineering Building III, North Carolina State University, Raleigh, NC, 27606, USA.
Tulino J; Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill, 116 Manning Drive, Chapel Hill, NC 27599, USA; Engineering Building III, North Carolina State University, Raleigh, NC, 27606, USA.
Tan X; Department of Biostatistics, University of North Carolina School of Public Health, 135 Dauer Drive, Chapel Hill, NC, 27599, USA.
Ligler FS; Department of Biomedical Engineering, Texas A&M University, 101 Bizzell Street, College Station, TX, 77843, USA.
Bae-Jump VL; Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, 450 West Drive, Chapel Hill, NC, 27599, USA.; Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, 101 Manning Drive, Chapel Hill, NC, 27599, USA.
Fenton SE; Curriculum in Toxicology & Environmental Medicine, University of North Carolina School of Medicine, University of North Carolina at Chapel Hill, 116 Manning Drive, Chapel Hill, NC, 27599, USA.; Mechanistic Toxicology Branch, Division of Translational Toxicology, National Institute of Environmental Health Sciences, 111 T.W. Alexander Drive, Research Triangle Park, Durham, NC, 27709, USA.
Rizvi I; Curriculum in Toxicology & Environmental Medicine, University of North Carolina School of Medicine, University of North Carolina at Chapel Hill, 116 Manning Drive, Chapel Hill, NC, 27599, USA. .; Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill, 116 Manning Drive, Chapel Hill, NC 27599, USA; Engineering Building III, North Carolina State University, Raleigh, NC, 27606, USA. .; Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, 450 West Drive, Chapel Hill, NC, 27599, USA. .; Center for Environmental Health and Susceptibility, University of North Carolina at Chapel Hill, 135 Dauer Drive, Chapel Hill, NC, 27599, USA. .
Pokaż więcej
Źródło:
Environmental health : a global access science source [Environ Health] 2023 Dec 14; Vol. 22 (1), pp. 87. Date of Electronic Publication: 2023 Dec 14.
Typ publikacji:
Journal Article
MeSH Terms:
Endometrial Neoplasms*/drug therapy
Endometrial Neoplasms*/chemically induced
Fluorocarbons*
Female ; Humans ; Carboplatin/toxicity ; Carboplatin/therapeutic use ; Cisplatin/pharmacology ; Cisplatin/therapeutic use ; Platinum/therapeutic use ; Cell Line
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
MNX1 Promotes Anti-HER2 Therapy Sensitivity via Transcriptional Regulation of CD-M6PR in HER2-Positive Breast Cancer.
Autorzy:
Chi W; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Xiu B; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Xiong M; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Wang X; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Li P; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Zhang Q; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Hou J; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Sang Y; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Zhou X; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Chen M; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Zheng S; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Zhang L; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Xue J; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Chi Y; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Wu J; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Dec 22; Vol. 25 (1). Date of Electronic Publication: 2023 Dec 22.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Breast Neoplasms*/genetics
Humans ; Female ; Quality of Life ; Gene Expression Regulation ; Genes, Homeobox ; Carboplatin/pharmacology ; Carboplatin/therapeutic use ; Transcription Factors ; Homeodomain Proteins
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Combined Interval Cytoreductive Surgery and Carboplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Advanced Primary High-Grade Serous Ovarian Cancer.
Autorzy:
Brault C; Department of Obstetrics and Gynecology, University of Montreal, Montreal, QC H3T 1J4, Canada.
Brind'Amour A; Department of Surgery, CHU de Québec-Université Laval, Quebec, QC G1V 4G2, Canada.
de Guerke L; Division of Surgical Oncology, Maisonneuve-Rosemont Hospital, Montreal, QC H1T 2M4, Canada.
Auclair MH; Division of Surgical Oncology, Maisonneuve-Rosemont Hospital, Montreal, QC H1T 2M4, Canada.
Sideris L; Division of Gynecologic Oncology, Maisonneuve-Rosemont Hospital, Montreal, QC H1T 2M4, Canada.
Dubé P; Division of Gynecologic Oncology, Maisonneuve-Rosemont Hospital, Montreal, QC H1T 2M4, Canada.
Soucisse M; Division of Gynecologic Oncology, Maisonneuve-Rosemont Hospital, Montreal, QC H1T 2M4, Canada.
Tremblay JF; Division of Gynecologic Oncology, Maisonneuve-Rosemont Hospital, Montreal, QC H1T 2M4, Canada.
Bernard L; Division of Gynecologic Oncology, Royal Victoria Hospital, Montreal, QC H4A 3J1, Canada.
Piedimonte S; Division of Surgical Oncology, Maisonneuve-Rosemont Hospital, Montreal, QC H1T 2M4, Canada.
Fortin S; Division of Surgical Oncology, Maisonneuve-Rosemont Hospital, Montreal, QC H1T 2M4, Canada.
Pokaż więcej
Źródło:
Current oncology (Toronto, Ont.) [Curr Oncol] 2023 Dec 01; Vol. 30 (12), pp. 10272-10282. Date of Electronic Publication: 2023 Dec 01.
Typ publikacji:
Journal Article
MeSH Terms:
Peritoneal Neoplasms*/drug therapy
Peritoneal Neoplasms*/surgery
Hyperthermia, Induced*
Ovarian Neoplasms*/drug therapy
Ovarian Neoplasms*/surgery
Humans ; Female ; Middle Aged ; Carboplatin/therapeutic use ; Hyperthermic Intraperitoneal Chemotherapy ; Cytoreduction Surgical Procedures ; Combined Modality Therapy ; Retrospective Studies ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Canada ; Carcinoma, Ovarian Epithelial/drug therapy ; Carcinoma, Ovarian Epithelial/surgery
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Autorzy:
Leung D; Fiona Elsey Cancer Research Institute, Ballarat Central Technology Central Park, Ballarat, Vic, 3353, Australia. .
Price ZK; Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, The University of Adelaide, Adelaide, SA, 5005, Australia.
Lokman NA; Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, The University of Adelaide, Adelaide, SA, 5005, Australia.
Wang W; Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, The University of Adelaide, Adelaide, SA, 5005, Australia.
Goonetilleke L; Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, The University of Adelaide, Adelaide, SA, 5005, Australia.
Kadife E; Fiona Elsey Cancer Research Institute, Ballarat Central Technology Central Park, Ballarat, Vic, 3353, Australia.
Oehler MK; Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, The University of Adelaide, Adelaide, SA, 5005, Australia.; Department of Gynecological Oncology, Royal Adelaide Hospital, Adelaide, SA, 5000, Australia.
Ricciardelli C; Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, The University of Adelaide, Adelaide, SA, 5005, Australia.
Kannourakis G; Fiona Elsey Cancer Research Institute, Ballarat Central Technology Central Park, Ballarat, Vic, 3353, Australia.; School of Science, Psychology and Sport, Federation University, Mt Helen, VIC, 3350, Australia.
Ahmed N; Fiona Elsey Cancer Research Institute, Ballarat Central Technology Central Park, Ballarat, Vic, 3353, Australia. .; School of Science, Psychology and Sport, Federation University, Mt Helen, VIC, 3350, Australia. .; Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, VIC, 3052, Australia. .; Centre for Reproductive Health, Hudson Institute of Medical Research and Department of Translational Medicine, Monash University, Clayton, VIC, 3168, Australia. .
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2022 Dec 03; Vol. 20 (1), pp. 556. Date of Electronic Publication: 2022 Dec 03.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carboplatin*/metabolism
Epithelial-Mesenchymal Transition*/genetics
Epithelial-Mesenchymal Transition*/physiology
Ovarian Neoplasms*/drug therapy
Ovarian Neoplasms*/genetics
Ovarian Neoplasms*/metabolism
Drug Resistance, Neoplasm*/genetics
Drug Resistance, Neoplasm*/physiology
Female ; Humans ; Aldehyde Reductase ; Carcinoma, Ovarian Epithelial/genetics ; CD8-Positive T-Lymphocytes ; Platinum ; Proteomics ; RNA, Messenger ; Tumor Microenvironment
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Study on the efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy regimen for III-IVA esophageal squamous cell carcinoma post-surgery.
Autorzy:
Li C; Department of Thoracic Surgery, The First People's Hospital of Chang-Zhou City, The Third Affiliated Hospital of Soochow University, 185 Juqian Road, Jiangsu, 213003, China.
Yu P; Department of Thoracic Surgery, The First People's Hospital of Chang-Zhou City, The Third Affiliated Hospital of Soochow University, 185 Juqian Road, Jiangsu, 213003, China.
Li H; Department of Thoracic Surgery, The First People's Hospital of Chang-Zhou City, The Third Affiliated Hospital of Soochow University, 185 Juqian Road, Jiangsu, 213003, China.
Yang X; Department of Oncology, The First People's Hospital of Chang-Zhou City, The Third Affiliated Hospital of Soochow University, 185 Juqian Road, Jiangsu, 213003, China.
Wang J; Department of Thoracic Surgery, The First People's Hospital of Chang-Zhou City, The Third Affiliated Hospital of Soochow University, 185 Juqian Road, Jiangsu, 213003, China.
Jiang B; Department of Thoracic Surgery, The First People's Hospital of Chang-Zhou City, The Third Affiliated Hospital of Soochow University, 185 Juqian Road, Jiangsu, 213003, China. .
Pokaż więcej
Źródło:
Journal of cardiothoracic surgery [J Cardiothorac Surg] 2024 Jan 25; Vol. 19 (1), pp. 26. Date of Electronic Publication: 2024 Jan 25.
Typ publikacji:
Journal Article
MeSH Terms:
Esophageal Squamous Cell Carcinoma*/surgery
Esophageal Squamous Cell Carcinoma*/drug therapy
Esophageal Neoplasms*/drug therapy
Esophageal Neoplasms*/surgery
Organoplatinum Compounds*
Humans ; Neoadjuvant Therapy ; Cisplatin/therapeutic use ; Carboplatin/therapeutic use ; Retrospective Studies ; Neoplasm Staging ; Paclitaxel ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Immunotherapy
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Gene expression alterations predict the pathological complete response in triple-negative breast cancer exploratory analysis of the NACATRINE trial.
Autorzy:
Freitas AJA; Molecular Oncology Research Center, Barretos Cancer Hospital, Teaching and Research Institute, Barretos, SP, Brazil. .
Nunes CR; Molecular Oncology Research Center, Barretos Cancer Hospital, Teaching and Research Institute, Barretos, SP, Brazil.
Mano MS; Grupo Oncoclínicas, São Paulo, Brazil.
Causin RL; Molecular Oncology Research Center, Barretos Cancer Hospital, Teaching and Research Institute, Barretos, SP, Brazil.
Santana IVV; Pathology Department, Barretos Cancer Hospital, Barretos, SP, Brazil.
de Oliveira MA; Nucleus of Epidemiology and Biostatistics, Barretos Cancer Hospital, Barretos, SP, Brazil.
Calfa S; Molecular Oncology Research Center, Barretos Cancer Hospital, Teaching and Research Institute, Barretos, SP, Brazil.
Silveira HCS; Molecular Oncology Research Center, Barretos Cancer Hospital, Teaching and Research Institute, Barretos, SP, Brazil.
de Pádua Souza C; Barretos Cancer Hospital, Barretos, SP, Brazil.
Marques MMC; Molecular Oncology Research Center, Barretos Cancer Hospital, Teaching and Research Institute, Barretos, SP, Brazil. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Dec 04; Vol. 13 (1), pp. 21411. Date of Electronic Publication: 2023 Dec 04.
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article
MeSH Terms:
Triple Negative Breast Neoplasms*/drug therapy
Triple Negative Breast Neoplasms*/genetics
Triple Negative Breast Neoplasms*/pathology
Humans ; Carboplatin/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Neoadjuvant Therapy ; Biomarkers ; Gene Expression
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Investigation of the cytotoxicity induced by cannabinoids on human ovarian carcinoma cells.
Autorzy:
Sooda K; Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield, UK.
Allison SJ; Department of Biological & Geographical Sciences, School of Applied Sciences, University of Huddersfield, Huddersfield, UK.
Javid FA; Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield, UK.
Pokaż więcej
Źródło:
Pharmacology research & perspectives [Pharmacol Res Perspect] 2023 Dec; Vol. 11 (6), pp. e01152.
Typ publikacji:
Journal Article
MeSH Terms:
Ovarian Neoplasms*/drug therapy
Cannabinoids*/pharmacology
Carcinoma*/drug therapy
Male ; Humans ; Female ; Cell Line, Tumor ; Carboplatin/pharmacology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials.
Autorzy:
de Moraes FCA; Oncology Research Center, Federal University of Pará, University Hospital João de Barros de Barreto, Rua dos Mundurucus, nº4487, Belém, 66073-000, PA, Brazil. .
Pasqualotto E; Federal University of Santa Catarina, Florianópolis, 88040-900, Santa Catarina, Brazil.
Lopes LM; Sciences Medical School of Santos, Santos, São Paulo, 11045-101, Brazil.
Cavalcanti Souza ME; University of Pernambuco, Recife, 50670-901, Pernambuco, Brazil.
de Oliveira Rodrigues ALS; University Center of João Pessoa, João Pessoa, Paraíba, 58053-000, Brazil.
de Almeida AM; Federal University of Mato Grosso, Sinop, 78550-704, Mato Grosso, Brazil.
Stecca C; Mackenzie Evangelical University Hospital, Curitiba, 80730-150, Paraná, Brazil.
Fernandes MR; Oncology Research Center, Federal University of Pará, University Hospital João de Barros de Barreto, Rua dos Mundurucus, nº4487, Belém, 66073-000, PA, Brazil.
Dos Santos NPC; Oncology Research Center, Federal University of Pará, University Hospital João de Barros de Barreto, Rua dos Mundurucus, nº4487, Belém, 66073-000, PA, Brazil.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 Nov 29; Vol. 23 (1), pp. 1166. Date of Electronic Publication: 2023 Nov 29.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:
Endometrial Neoplasms*/drug therapy
Lung Neoplasms*/drug therapy
Female ; Humans ; Carboplatin ; Paclitaxel ; Immune Checkpoint Inhibitors/therapeutic use ; Programmed Cell Death 1 Receptor/therapeutic use ; Randomized Controlled Trials as Topic ; B7-H1 Antigen
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non-small cell lung cancer: A randomized, double-blind, phase III study.
Autorzy:
Chen L; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangdong, Guangzhou, China.
Rangel JDG; Clinical Medical Research S.C, Veracruz, México.
Cil T; Health and Science University, Adana City Education and Research Hospital, Adana, Turkey.
Li X; The First Affiliated Hospital of Zhengzhou University, Henan, Zhengzhou, China.
Cicin I; Trakya University Medical Faculty, Edirne, Turkey.
Shen Y; The First Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang, Hangzhou, China.
Liu Z; Jiangxi Cancer Hospital, Jiangxi, Nanchang, China.
Ozyilkan O; Baskent University Adana Application and Research Center, Adana, Turkey.
Igor B; CNE 'City Clinical Hospital No4', Dnipro, Ukraine.
Chen J; Tianjin Medical University General Hospital, Tianjin, China.
Oleksandr K; Podilskyi Regional Oncological Center, Vinnytsia, Ukraine.
Chen Z; The Second Hospital of Anhui Medical University, Anhui, Hefei, China.
Zhang H; Tangdu Hospital, Fourth Military Medical University, Shanxi, Xi'an, China.
Fu Z; Bio-Thera Solutions, Ltd., Guangdong, Guangzhou, China.
Dong Q; Bio-Thera Solutions, Ltd., Guangdong, Guangzhou, China.
Song S; Bio-Thera Solutions, Ltd., Guangdong, Guangzhou, China.
Yu JC; Bio-Thera Solutions, Ltd., Guangdong, Guangzhou, China.
Zhang L; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangdong, Guangzhou, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Nov; Vol. 12 (22), pp. 20847-20863. Date of Electronic Publication: 2023 Nov 07.
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Biosimilar Pharmaceuticals*/adverse effects
Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/drug therapy
Humans ; Antineoplastic Combined Chemotherapy Protocols ; Bevacizumab/adverse effects ; Carboplatin/therapeutic use ; Double-Blind Method ; Paclitaxel/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy of paclitaxel-carboplatin with bevacizumab as a late-line therapy for patients with advanced nonsquamous non-small cell lung cancer: A platinum rechallenge.
Autorzy:
Sugisaka J; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Toi Y; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Kawashima Y; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Domeki Y; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Aiba T; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Kawana S; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Nakamura A; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Yamanda S; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Kimura Y; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Sugawara S; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2023 Nov; Vol. 14 (31), pp. 3140-3146. Date of Electronic Publication: 2023 Sep 12.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*
Lung Neoplasms*
Humans ; Bevacizumab ; Carboplatin ; Platinum/therapeutic use ; Retrospective Studies ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Paclitaxel
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Safety and Tolerability of Weekly Genexol-PM, a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel, with Carboplatin in Gynecologic Cancer: A Phase I Study.
Autorzy:
Nam SH; Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Lee SW; Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Lee YJ; Department of Obstetrics and Gynecology, GangNeung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea.
Kim YM; Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Pokaż więcej
Źródło:
Cancer research and treatment [Cancer Res Treat] 2023 Oct; Vol. 55 (4), pp. 1346-1354. Date of Electronic Publication: 2023 May 15.
Typ publikacji:
Clinical Trial, Phase I; Journal Article
MeSH Terms:
Micelles*
Neoplasms*/drug therapy
Female ; Humans ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carboplatin/adverse effects ; Paclitaxel/adverse effects ; Polymers/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?
Autorzy:
Ayhan S; Department of Obstetrics and Gynecology, University of Health Sciences, Bilkent City Hospital, Ankara, Turkey.
Hancerliogullari N; Department of Obstetrics and Gynecology, University of Health Sciences, Bilkent City Hospital, Ankara, Turkey.
Guney G; Department of Reproductive Endocrinology and Infertility, Balikesir University School of Medicine, Cagis Campus,10145, 10145, Balikesir, Turkey. .
Gozukucuk M; Department of Obstetrics and Gynecology, University of Health Sciences, Ankara Training and Research Hospital, Ankara, Turkey.
Caydere M; Department of Pathology, University of Health Sciences, Ankara Training and Research Hospital, Ankara, Turkey.
Guney SS; Department of Midwifery, Faculty of Health Sciences, Balikesir University, Balikesir, Turkey.
Tokmak A; Department of Obstetrics and Gynecology, University of Health Sciences, Bilkent City Hospital, Ankara, Turkey.
Ustun Y; Department of Obstetrics and Gynecology, University of Health Sciences, Ankara Training and Research Hospital, Ankara, Turkey.
Pokaż więcej
Źródło:
Journal of ovarian research [J Ovarian Res] 2023 Sep 02; Vol. 16 (1), pp. 184. Date of Electronic Publication: 2023 Sep 02.
Typ publikacji:
Journal Article
MeSH Terms:
Ovarian Reserve*
Metformin*/pharmacology
Female ; Animals ; Rats ; Carboplatin/adverse effects ; Catalase ; Anti-Mullerian Hormone ; Malondialdehyde
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Adjustment of creatinine clearance for carboplatin dosing in Calvert's formula and clinical efficacy for lung cancer.
Autorzy:
Hatta T; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hase T; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hara T; Department of Respiratory Medicine, Anjo Kosei Hospital, Anjo, Japan.
Kimura T; Department of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Japan.
Kojima E; Department of Respiratory Medicine, Komaki City Hospital, Komaki, Japan.
Abe T; Department of Respiratory Medicine, Ogaki Municipal Hospital, Ogaki, Japan.
Horio Y; Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Goto Y; Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Japan.
Ozawa N; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yogo N; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Shibata H; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Shimokata T; Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.
Oguri T; Department of Education and Research Center for Community Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Yamamoto M; Department of Respiratory Medicine, Nagoya Ekisaikai Hospital, Nagoya, Japan.
Yanagisawa K; Division of Molecular and Cancer Medicine, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Ando M; Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan.
Ando Y; Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.
Kondo M; Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Japan.
Ishii M; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hasegawa Y; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.; National Hospital Organization, Nagoya Medical Center, Nagoya, Japan.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Aug; Vol. 12 (15), pp. 15955-15969. Date of Electronic Publication: 2023 Jun 23.
Typ publikacji:
Observational Study; Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Lung Neoplasms*/drug therapy
Antineoplastic Agents*/therapeutic use
Carcinoma, Non-Small-Cell Lung*/drug therapy
Humans ; Aged ; Carboplatin ; Creatinine/therapeutic use ; Treatment Outcome ; Glomerular Filtration Rate
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 1382

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies